The listing was better than grey market estimates where IKS Health shares were commanding a premium of 32%. Previous Post This pharma stock is the top Nifty 50 gainer after Nomura upgrades rating to ‘buy’ Next Post This underperforming defence stock is down 33% from its peak but analysts keep the faith Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
